Proto-oncogenes are a cohort of cellular genes which are avidly conserved across a broad span of vertebrate evolution. Evidence now exists that these genes play a role in normal cellular processes such as growth and differentiation. In addition, considerable circumstantial evidence exists linking various alterations in these genes to the induction and/or maintenance of human malignancies. We have been involved in the study of the expression of proto-oncogenes in physiologic states (murine development) and pathologic states (human malignancies). We propose to continue this work using reagents generated in our laboratory during the preceeding funding period, as well as reagents from other laboratories. The general approach is multifaceted, and is as follows. Firstly, we will attempt to obtain information on some aspects of the biologic properties and functions of those proto-oncogenes for which we have useful reagents (i.e., N-myc, c-myb, and c-fos); secondly, we plan to conduct studies on the time-related and tissue-specific expression of these and other proto-oncogenes during murine development; thirdly, we will expand previous studies on the role of the N-myc, c-myb and HER-2/neu proto-oncogenes in specific human malignancies (i.e., neuroblastoma and small cell carcinoma of the lung, acute leukemias, and carcinoma of the breast, respectively); and finally, we propose to conduct a survey of common human malignancies for alterations in proto-oncogenes at the DNA level and/or their expression at the RNA and protein levels, in an attempt to correlate any observed alterations with specific tumor types, or with various clinical parameters of a given tumor.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA036827-04
Application #
3174402
Study Section
Pathology B Study Section (PTHB)
Project Start
1984-07-01
Project End
1992-06-30
Budget Start
1987-07-01
Budget End
1988-06-30
Support Year
4
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Wilson, C A; Ramos, L; Villasenor, M R et al. (1999) Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 21:236-40
Pietras, R J; Poen, J C; Gallardo, D et al. (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347-55
Pietras, R J; Pegram, M D; Finn, R S et al. (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235-49
Pegram, M D; Finn, R S; Arzoo, K et al. (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15:537-47
Reese, D M; Slamon, D J (1997) HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15:1-8
Wilson, C A; Payton, M N; Elliott, G S et al. (1997) Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene 14:1-16
Pauletti, G; Godolphin, W; Press, M F et al. (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72
Pisani, A L; Barbuto, D A; Chen, D et al. (1995) HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 85:729-34
Silverstein, M J; Poller, D N; Waisman, J R et al. (1995) Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345:1154-7
Pietras, R J; Arboleda, J; Reese, D M et al. (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-46

Showing the most recent 10 out of 29 publications